Schistosomiasis is a major disease of the developing world. Despite integrated control measures, schistosomiasis continues to spread to new regions. So, there is a pressing need to identify new antigens and to explore new adjuvants to improve vaccine efficacy. The aim of the present study was to evaluate the efficacy of an adjuvant dendritic cell (DC) combined with S. mansoni SEA and SWAP antigens as vaccination in mice experimentally infected with S. mansoni. The study was carried out on 70 laboratory bred Swiss albino male mice. The mice were divided into seven groups each contained 10 mice. The vaccine was given in three doses injected subcutaneously at two weeks' interval. Porto-mesenteric worm burden, hepatic and intestinal egg counts, hepatic granuloma number and diameter, and oogram pattern were assessed to evaluate the antischistosomal effect of vaccines. Ig G, IL-10 & IL-12p40 levels were tested to assess immunological effect. Results revealed that the use of SEA + DCs were associated with a significant decrease in worm burden and tissue egg load together with an increased percentage of dead eggs. In addition, there was a significant reduction in granuloma formation. Also percent of CD4 +ve cells in liver and IL-10 & IL 12p40was the highest in SEA+DCs group. Importantly, our data suggest a need to re-evaluate host immune responses to many schistosome antigens. There is also a need for a standardized & effective adjuvant formulation and schistosomiasis vaccine development.

Download this article as